Brachytherapy for prostate cancer: a systematic review (Q37591954)

21 August 2017

1 reference

title

Brachytherapy for prostate cancer: a systematic review (English)

1 reference

21 August 2017

1 reference

1 reference

1 reference

2

Nikolaos Kelekis

0 references

author name string

Georgios Koukourakis

1

1 reference

21 August 2017

Nikolaos Kelekis

2

1 reference

21 August 2017

Vassilios Armonis

3

1 reference

21 August 2017

Vassilios Kouloulias

4

1 reference

21 August 2017

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

327945

1 reference

Creative Commons Attribution 3.0 Unported

21 August 2017

start time

1 January 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Guideline for the management of clinically localized prostate cancer: 2007 update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

External-beam radiotherapy for localized prostate cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Results of permanent prostate brachytherapy, 13 years of experience at a single institution

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Importance of post-implant dosimetry in permanent prostate brachytherapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

High dose rate brachytherapy as a boost for the treatment of localized prostate cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Transperineal permanent seed implantation of "low-risk" prostate cancer: 5-year-experiences in 118 patients

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Update: NCCN prostate cancer Clinical Practice Guidelines.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

[Permanent iodine 125 implant brachytherapy in localized prostate cancer: results of the first 4 years of experience].

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Technical improvement in permanent seed implantation: a two-stage brachytherapy system. Description and comparison with current technique.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Prostate gland motion and deformation caused by needle placement during brachytherapy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735748

The α/β ratio for prostate cancer: What is it, really?

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2009%2F327945

Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control

21 January 2018

1 reference

12 December 2020

Influence of prostate volume on dosimetry results in real-time 125I seed implantation

1 reference

12 December 2020

12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer

1 reference

12 December 2020

GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer

1 reference

12 December 2020

Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer

1 reference

12 December 2020

Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience

1 reference

12 December 2020

Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation

1 reference

12 December 2020

Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer

1 reference

12 December 2020

Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension

1 reference

12 December 2020

Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate

1 reference

12 December 2020

Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer

1 reference

12 December 2020

Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate

1 reference

12 December 2020

High dose rate brachytherapy of localized prostate cancer

1 reference

12 December 2020

[I125 low dose rate brachytherapy in localized prostate cancer. Preliminary results after 5 years]

1 reference

12 December 2020

Disease-specific survival following the brachytherapy management of prostate cancer

1 reference

12 December 2020

Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?

1 reference

12 December 2020

A dose-response study for I-125 prostate implants

1 reference

12 December 2020

Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer

1 reference

12 December 2020

Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam

1 reference

12 December 2020

Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy

1 reference

12 December 2020

Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy

1 reference

12 December 2020

Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results

1 reference

12 December 2020

High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer

1 reference

12 December 2020

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

12 December 2020

Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome

1 reference

12 December 2020

10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology

1 reference

12 December 2020

Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation

1 reference

12 December 2020

Identifiers

DOI

10.1155/2009/327945

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

19730753

1 reference